(IN BRIEF) The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS), following positive results from the HERCULES phase 3 study. The study showed tolebrutinib delayed disability progression by 31% and … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Dr. Erik Wallström, FDA, Progressive Multiple Sclerosis, safety, Sanofi, tolebrutinib
(IN BRIEF) Sanofi’s phase 3 study for its drug tolebrutinib has shown promising results in treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), a condition with no current approved therapies. The HERCULES study revealed that tolebrutinib successfully delayed disability progression in … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged activated microglia, annualized relapse rate (ARR), B lymphocytes, brain-penetrant BTK inhibitor, central nervous system (CNS), confirmed disability progression (CDP), Copenhagen, Denmark, disability accumulation, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), GEMINI 1 and 2 phase 3 studies, HERCULES phase 3 study, Houman Ashrafian, innate immunity, multiple sclerosis, neuroinflammation, non-relapsing secondary progressive MS (nrSPMS), PERSEUS phase 3 study, primary progressive MS, Sanofi, teriflunomide, tolebrutinib
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?